(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.45%.
Sutro Biopharma's earnings in 2026 is -$153,602,000.On average, 15 Wall Street analysts forecast STRO's earnings for 2026 to be -$144,212,531, with the lowest STRO earnings forecast at -$165,313,328, and the highest STRO earnings forecast at -$96,564,233. On average, 15 Wall Street analysts forecast STRO's earnings for 2027 to be -$124,864,886, with the lowest STRO earnings forecast at -$172,945,672, and the highest STRO earnings forecast at -$84,558,950.
In 2028, STRO is forecast to generate -$123,289,037 in earnings, with the lowest earnings forecast at -$167,262,011 and the highest earnings forecast at -$72,901,646.